BNT116 + DOCETAXEL for arthrogryposis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 2 Dec 2021: Trial registered, NCT05142189
  2. 17 Jun 2022: Trial started, NCT05142189

The trials

NCT05142189: Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

State
Under way
Phase
Phase 1
People
320 planned
Started
17 Jun 2022
Primary completion
Feb 2030
Arms
Cohort 3 - BNT116 + Docetaxel
Results
None posted
  1. 2 Dec 2021: Trial registered
  2. 17 Jun 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.